CD274 and neoplasm: The PD-1/program death ligand-1 (PD-L1) checkpoint allows for tumoral PD-L1 to interact with T-cell PD-1 and prevent T-cell-mediated immune activation; blocking this interaction allows the host immune system to recognize and attack the tumor cells [5].